Biocon secures global settlement with Genentech for Pebrilzo launch
The agreement sets licensed launch dates for Biocon’s pertuzumab biosimilar in the EU, UK, US and other markets
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Uncategorized
DoP Secretary Manoj Joshi visits Amneal Pharmaceuticals in Ahmedabad
Manoj Joshi, Secretary, Department of Pharmaceuticals, Government of India, visited Amneal Pharmaceuticals’ corporate office in…
Sun Pharma joins US drug pricing deal, gets tariff relief
The company will offer MFN pricing to state Medicaid programmes and for future innovative medicines under the agreement with the…
Glenmark advances multi-country phase 3 clinical trial of Trastuzumab rezetecan in PROC
Glenmark Specialty S.A, a wholly owned subsidiary of Glenmark Pharmaceuticals (Glenmark) announced the advancement of its…
Morepen dispatches its first batch under CDMO mandate
Morepen Laboratories issued an update on its recently announced Rs. 825 crore CDMO mandate. The first commercial dispatch, valued…
Shilpa Medicare enters strategic partnership with NXI Therapeutics AG
Shilpa Medicare, a global integrated pharmaceutical and CDMO company, announced the signing of a long-term development and…
Sightsavers India and AbbVie India advance nationwide Glaucoma awareness efforts in Jaipur
Sightsavers India, in collaboration with AbbVie Therapeutics India, continued its national drive to address glaucoma-related…
BIRAC fuels innovation with Rs. 4,200 crore funding across 15 lakh startups and entrepreneurs
Biotechnology Industry Research Assistance Council (BIRAC), a Public Sector Enterprise set up by the Department of Biotechnology…
IDMA PAC 2025: Industry leaders call for AI and sustainable GMP practices
The 24th IDMA Pharmaceutical Analysts’ Conference (PAC) commenced on December 16, to deliberate on the evolving landscape of…
Odisha Pharma Summit 2025 positions Odisha as eastern India’s emerging life sciences hub: Odisha CM
“Odisha will be a leading destination for pharmaceutical and medical‑device investments – the most competitive hub for innovation…
LANXESS appoints Oliver Stratmann for another term as Chief Financial Officer
LANXESS has reappointed Oliver Stratmann as a member of the Board of Management and extended his contract as Chief Financial…
Parexel completes CRO registration with CDSCO under new G.S.R 581(E) regulation
Parexel aligns with CDSCO regulatory framework, ensuring continued clinical trial operations in India
ACG Packaging Materials GHG commitment validated and approved by SBTi
ACG has committed to reducing absolute Scope 1 and 2 GHG emissions by 90 per cent
ENTOD Pharmaceuticals partners with Infigo Eyecare to introduce advanced under-eye treatments
ENTOD Pharmaceuticals and Infigo Eyecare Hospital collaborate to enhance treatment options for under-eye pigmentation, puffiness,…
Revamping multi-tier distribution: Ensuring consistent availability for India’s pharma growth
Chandrachur Datta, Partner, Vector Consulting Group explores how revamping the multi-tier distribution system with a demand-driven…
Bridging the gap between pharmaceutical research and market application: The role of universities…
Dr Mallikarjuna B.P, Dean, School of Pharmaceutical Sciences, Mohan Babu University highlights how universities play a crucial…
Alembic Pharma gets form 483 with five procedural observations by USFDA
The GMP inspection was conducted at the company’s Jarod facility
JB Pharma announces ESG commitments with launch of third sustainability report
JB Pharma outlines goals to reduce emissions, increase renewable energy use, and achieve water positivity by 2033 in its latest…
Alembic Pharmaceuticals announces USFDA final approval for Nelarabine injection, 250 mg/50 mL (5…
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Arranon Injection, 250 mg/50 mL (5…
FDA updates guidance to address spread of misinformation
The revised draft supports the efforts of medical product companies that share this interest in helping the public get factual,…